91国内精品久久久久精品一本91福利共享久久精品|糖心vlog在线人妻高清字幕91啦|人妻在线中文字幕中文字幕人妻久久久久|成人麻豆视频|不卡av中文字幕|国产高清精品一区|国产精品久久久久久吹潮天美传媒|中文字幕一区精品|91丨色丨国产熟女|91九色丨porny丨,天美传媒97a∨久久久久久精品国产尤物,91久久精品久久国产性色也91电影一区二区三区中文精品字幕 ,国产在线91九色

全球首創(chuàng)采用iNSC為神經(jīng)系統(tǒng)疾病干細(xì)胞療法的種子細(xì)胞

全球首個完成iNSC-DAP帕金森細(xì)胞療法研究者發(fā)起臨床試驗（IIT ）隨訪一年,，成果積極

追求安全,、長效神經(jīng)系統(tǒng)疾病干細(xì)胞新療法

北京慧心醫(yī)谷生物科技有限責(zé)任公司成立于2021年7月，此前，我們的科學(xué)家們深耕干細(xì)胞再生醫(yī)學(xué)治療領(lǐng)域的研究已十年有余,。我們致力于將擁有自主知識產(chǎn)權(quán)的國際領(lǐng)先的細(xì)胞重編程技術(shù),、基因治療技術(shù)應(yīng)用于神經(jīng)系統(tǒng)疾病的藥物研究以及創(chuàng)新療法的開發(fā)

目前,，我們已建立三大核心技術(shù)平臺,，分別為細(xì)胞重編程平臺、誘導(dǎo)神經(jīng)干細(xì)胞（induced neural stem cells, iNSCs）分化平臺,，以及類器官分化平臺,。基于此三大技術(shù)平臺，開辟神經(jīng)性疾病的創(chuàng)新療法的未來

首個在研創(chuàng)新藥是利用誘導(dǎo)神經(jīng)干細(xì)胞（iNSCs）分化成多巴胺能神經(jīng)前體細(xì)胞（iNSC-DAP）,，經(jīng)顱內(nèi)注射,，精準(zhǔn)修復(fù)受損神經(jīng)細(xì)胞，旨在從根本上終止或延緩帕金森病（PD）的進(jìn)程,。該項目目前進(jìn)度處于國際第一梯隊,，安全性更高，制備周期短,，可以應(yīng)用于自體和異體移植

2022年3月,，公司建于北京中關(guān)村生命科學(xué)園的GMP級別細(xì)胞制品生產(chǎn)車間正式投入使用,，開展國家藥監(jiān)局藥物臨床試驗申請（即IND申報）相關(guān)研究工作

2023年7月18日,，全球首例使用iNSC-DAP（誘導(dǎo)神經(jīng)干細(xì)胞來源的多巴胺能神經(jīng)前體細(xì)胞）自體細(xì)胞移植治療帕金森病的神經(jīng)外科手術(shù)在首都醫(yī)科大學(xué)宣武醫(yī)院成功完成。隨訪12個月,，取得良好的安全性和有效性,。

The world's first seed cell to use iNSC for stem cell therapy for neurological diseases； The world's first researcher to complete iNSC-DAP Parkinson's cell therapy initiated a clinical trial (IIT) for one year of follow-up, with positive results,； Pursuing safe, long-lasting new stem cell therapies for neurological diseases

Wiseheart MedVal Biotech Co., Ltd. was established in July 2021. Prior to this, our scientists had been deeply involved in research in the field of stem cell regenerative medicine treatment for more than ten years. We are committed to applying internationally leading cell reprogramming technology and gene therapy technology with independent intellectual property rights to drug research on neurological diseases and the development of innovative therapies.

At present, we have established three core technology platforms, namely the cell reprogramming platform, the induced neural stem cell (iNSCs) differentiation platform, and the organoid differentiation platform. Based on these three major technology platforms, we will open up the future of innovative treatments for neurological diseases. The first innovative drug under development uses induced neural stem cells (iNSCs) to differentiate into dopaminergic neural precursor cells (iNSC-DAP), which can be injected intracranially to precisely repair damaged nerve cells, aiming to fundamentally terminate or delay Parkinson's disease. disease (PD) progression. The current progress of this project is in the first echelon in the world. It is safer and has a short preparation cycle. It can be used in autologous and allogeneic transplantation. In March 2022, the company's GMP-like cell product production workshop built in Beijing Zhongguancun Life Science Park was officially put into use, and research work related to the National Food and Drug Administration's drug clinical trial application (i.e. IND application) was carried out. On July 18, 2023, the world's first neurosurgery using iNSC-DAP (induced neural stem cell-derived dopaminergic neural precursor cells) autologous cell transplantation to treat Parkinson's disease was successfully completed at Xuanwu Hospital of Capital Medical University. The 12-month follow-up showed good safety and effectiveness.

以科學(xué)之慧,，以仁愛之心,，治疾病之本

With the wisdom of science , and the heart of benevolence, cure the root causes of diseases.